TNF ANTAGONISTS AND TNF INHIBITORS COMPRISING THE SAME AS THE ACTIVE INGREDIENT

(19)

(11)

EP 1 717 246 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	07.10.2015 Bulletin 2015/41

(45)	Mention of the grant of the patent:
	12.08.2015 Bulletin 2015/33

(21)	Application number: 05703305.2

(22)	Date of filing: 05.01.2005

(51)

International Patent Classification (IPC):

C07K 14/525^(2006.01)
A61K 47/48^(2006.01)

A61K 38/00^(2006.01)
C12N 15/09^(2006.01)

(86)	International application number:
	PCT/JP2005/000032

(87)	International publication number:
	WO 2005/066206 (21.07.2005 Gazette 2005/29)

(54)	TNF ANTAGONISTS AND TNF INHIBITORS COMPRISING THE SAME AS THE ACTIVE INGREDIENT TNF-ANTAGONISTEN UND DIESE ALS WIRKSTOFF ENTHALTENDE TNF-INHIBITOREN ANTAGONISTES DU TNF, ET INHIBITEURS DU TNF LES CONTENANT EN TANT QU'INGREDIENT ACTIF

(84)	Designated Contracting States:
	DE GB

(30)

Priority:

06.01.2004 JP 2004001427

(43)	Date of publication of application:
	02.11.2006 Bulletin 2006/44

(73)	Proprietors:
	National Institutes of Biomedical Innovation, Health and Nutrition Osaka 567-0085 (JP) Mayumi, Tadanori Kobe-shi, Hyogo 6512273 (JP) Tsutsumi, Yasuo Toyono-gun, Osaka 563-0105 (JP) Nakagawa, Shinsaku Yao-shi, Osaka 581-0045 (JP)

(72)	Inventors:
	MAYUMI, Tadanori Nishi-ku, Kobe-shi, Hyogo 6512273 (JP) TSUTSUMI, Yasuo Osaka 5630105 (JP) NAKAGAWA, Shinsaku Osaka 5810045 (JP) OHTA, Tsunetaka Okayama-shi, Okayama 7000907 (JP)

(74)	Representative: Daniels, Jeffrey Nicholas et al
	Page White & Farrer Bedford House John Street London WC1N 2BF London WC1N 2BF (GB)

(56)

References cited: :

EP-A- 0 486 908
EP-A2- 1 354 893

EP-A- 0 563 714
US-A- 5 606 023

ZHANG X M ET AL: "SITE-DIRECTED MUTATIONAL ANALYSIS OF HUMAN TUMOR NECROSIS FACTOR-ALPHA RECEPTOR BINDING SITE AND STRUCTURE-FUNCTIONAL RELATIONSHIP" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 267, no. 33, 25 November 1992 (1992-11-25), pages 24069-24075, XP002922635 ISSN: 0021-9258
LOETSCHER H. ET AL.: 'Human tumor necrosis factor alpha (TNF alpha) mutants with exclusive especificity for the 55-kDa or 75-kDa TNF receptors.' J. BIOL.CHEM. vol. 268, 1993, pages 26350 - 26357, XP002304715
TSUTSUMI Y. ET AL.: 'Phage hyomen teijiho o kushishita kinosei jinko tanpakushitsu no soshutsu to DDS eno tenkial.' DRUG DELIVERY SYSTEM. vol. 18, 2003, pages 536 - 544, XP002992180
OSTADE VAN X ET AL: "HUMAN TUMOR NECROSIS FACTOR MUTANTS WITH PREFERENTIAL BINDING TO AND ACTIVITY ON EITHER THE R55 OR R15 RECEPTOR", EUROPEAN JOURNAL OF BIOCHEMISTRY, BLACKWELL PUBLISHING, BERLIN, DE, vol. 3, no. 220, 1 January 1994 (1994-01-01), pages 771-779, XP008003605, ISSN: 0014-2956, DOI: 10.1111/J.1432-1033.1994.TB18678.X

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).